Why is the P8A.SI stock down today?

P8A.SI stock is down due to weak intraday trading, negative EPS of **-0.05**, long receivables days (**255.59**), and thin volume versus average. Market activity suggests stock-specific concerns rather than a broad Healthcare sector sell-off.

What is Meyka AI’s view on P8A.SI stock?

Meyka AI rates P8A.SI with a **score 62.05 (Grade B, HOLD)**. The model highlights low PB valuation against weak profitability. This is informational and not investment advice.

What price targets exist for P8A.SI stock?

Meyka AI's forecast model projects monthly **SGD 0.150**, quarterly **SGD 0.230**, and yearly **SGD 0.304**, implying roughly **111.11%** upside from **SGD 0.144**. Forecasts are projections and not guarantees.

What are main risks for P8A.SI stock holders?

Key risks for P8A.SI stock include continued margin losses, slow receivables conversion, low daily liquidity on SES, and execution risk in growing diagnostics revenue. Monitor cash flow and quarterly updates closely.

SG Stocks

Down 9.72% intraday on SES: P8A.SI Cordlife 21 Feb 2026 watch liquidity

ByDanny Kontos February 21, 2026

The P8A.SI stock is trading lower intraday after showing a 9.72% one-day decline on the Singapore Exchange (SES) on 21 Feb 2026. At SGD 0.144 the share price sits near its short-term averages while volume is muted versus the 50-day average. Investors are watching valuation gaps: negative EPS of -0.05 and a price-to-book near 0.30 contrast with tight cash reserves. This intraday drop places Cordlife Group Limited under the top losers spotlight in the Healthcare sector and raises questions about liquidity and near-term growth.